NCT01713153

Comparing Misoprostol and Oxytocin in Uniject for Postpartum Hemorrhage (PPH) Prevention in Senegal

Preventing Postpartum Hemorrhage: Examining Two Strategies for PPH Prevention in Communities: Misoprostol and Oxytocin Uniject in Senegal

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,365 (actual)
• Sponsor: Gynuity Health Projects · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Accepted

Summary

This is a large, community-based, cluster-randomized trial to compare routine prophylactic use of 600 mcg oral misoprostol and 10 IU oxytocin delivered by UnijectTM intramuscularly during the third stage of labor

Detailed description

This study will assess the programmatic implications (including feasibility, acceptability, risks and benefits) at the community level of the introduction of misoprostol and/or oxytocin in UnijectTM for the prevention of PPH and will help to identify the appropriate niche for both drugs.

Conditions

• Postpartum Hemorrhage

Interventions

Type	Name	Description
DRUG	Misoprostol	600 mcg misoprostol oral
DEVICE	UnijectTM	10 IU oxytocin delivered intramuscularly with UnijectTM

Timeline

• Start date: 2012-06-01
• Primary completion: 2014-01-01
• Completion: 2014-01-01
• First posted: 2012-10-24
• Last updated: 2016-02-25

Locations

1 site across 1 country: Senegal